Back to Browse Journals » OncoTargets and Therapy » Volume 3

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

Authors Carmen Diana Schweighofer, Clemens-Martin Wendtner

Published 30 March 2010 Volume 2010:3 Pages 53—67


Review by Single-blind

Peer reviewer comments 2

Carmen Diana Schweighofer1, Clemens-Martin Wendtner2

1Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA; 2Department of Internal Medicine I, University of Cologne, Cologne, Germany

Abstract: The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved as a first-line single agent, even though the hurdle with chlorambucil as the contender was not set very high. Within clinical trials, the drug demonstrated an excellent ability to eliminate minimal residual disease in blood and bone marrow, which has been correlated with a corresponding survival advantage in patients. However, in the maintenance setting, infectious complications due to severe T cell suppression have been highlighted and do not allow clinicans to use alemtuzumab outside of clinical trials. This review discusses potential therapeutic niches and future applications of alemtuzumab with a focus on CLL front-line treatment.
Keywords: CLL, alemtuzumab, Campath, front-line, first-line treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Reduction of exercise capacity in sarcoidosis in relation to disease severity

Kallianos A, Zarogoulidis P, Ampatzoglou F, Trakada G, Gialafos E, Pitsiou G, Pataka A, Veletza L, Zarogoulidis K, Hohenforst-Schmidt W, Petridis D, Kioumis I, Rapti A

Patient Preference and Adherence 2015, 9:1179-1188

Published Date: 18 August 2015

Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial

Ueda A, Hosokawa A, Ogawa K, Yoshita H, Ando T, Kajiura S, Fujinami H, Kawai K, Nishikawa J, Tajiri K, Minemura M, Sugiyama T

OncoTargets and Therapy 2013, 6:491-496

Published Date: 8 May 2013

Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC

Ballas MS, Chachoua A

OncoTargets and Therapy 2011, 4:43-58

Published Date: 30 May 2011

Update on options for treatment of metastatic castration-resistant prostate cancer

Prakash Vishnu, Winston W Tan

OncoTargets and Therapy 2010, 3:39-51

Published Date: 23 March 2010

New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab

Argirios Moustakas, Teri N Kreisl

OncoTargets and Therapy 2010, 3:27-38

Published Date: 11 March 2010

Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer

Francesco Di Costanzo, Silvia Gasperoni, Virginia Rotella, Federica Di Costanzo

OncoTargets and Therapy 2009, 2:179-188

Published Date: 7 July 2009

Transport characteristics of nanoparticle-based ferrofluids in a gel model of the brain

Soubir Basak, David Brogan, Hans Dietrich, Rogers Ritter, et al.

International Journal of Nanomedicine 2009, 4:9-26

Published Date: 1 April 2009

Candesartan cilexetil in the treatment of chronic heart failure

Jean-Philippe Baguet, Gilles Barone-Rochette, Yannick Neuder

Vascular Health and Risk Management 2009, 5:257-264

Published Date: 4 March 2009